News & Updates
Filter by Specialty:
Investigational imaging agent holds promise for diagnosing renal cancer
In the pivotal phase III ZIRCON study, PET/CT imaging with 89Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).
Investigational imaging agent holds promise for diagnosing renal cancer
17 Apr 2023
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
The angiotensin receptor neprilysin inhibitor sacubitril/valsartan, used for heart failure, appears to have potent effects on 24‐hour blood pressure (BP) in Japanese patients with mild‐to‐moderate hypertension and in the subgroup of those with nondipping BP pattern, as shown in a study.
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
15 Apr 2023
Excessive air swallowing linked to dyspepsia, poor response to PPI therapy
Swallowing more air appears to induce both dyspepsia and refractoriness to typical symptoms of gastroesophageal reflux disease (GERD) to proton pump inhibitor (PPI) therapy, suggests a study.
Excessive air swallowing linked to dyspepsia, poor response to PPI therapy
14 Apr 2023
Topical NSAID treatment after selective laser trabeculoplasty of no benefit in glaucoma patients
The use of topical nonsteroidal anti-inflammatory drug (NSAID) does not seem to enhance the efficacy of selective laser trabeculoplasty for patients with glaucoma, as shown in a study.
Topical NSAID treatment after selective laser trabeculoplasty of no benefit in glaucoma patients
14 Apr 2023
Apremilast safe, effective in moderate-to-severe genital psoriasis
Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.
Apremilast safe, effective in moderate-to-severe genital psoriasis
13 Apr 2023
Mirabegron may improve sexual function in adults with OAB
Mirabegron, a ß3 adrenoceptor agonist, delivers benefit for both men and women with overactive bladder (OAB) who are experiencing sexual dysfunction, a systematic review and meta-analysis reports.